帕博利珠单抗联合地那昔利布治疗血液系统恶性肿瘤:1b期KEYNOTE-155研究
多队列1期KEYNOTE-155研究评估帕博利珠单抗联合地那昔利布在复发或难治性慢性淋巴细胞白血病、弥漫性大B细胞淋巴瘤和多发性骨髓瘤患者中的安全性和抗肿瘤活性。72例患者入组并接受至少1剂研究治疗。联合方案总体耐受良好,未出现意外毒性。客观缓解率分别为复发或难治性慢性淋巴细胞白血病29.4%(5/17)、复发或难治性弥漫性大B细胞淋巴瘤21.1%(8/38)、复发或难治性多发性骨髓瘤0%(0/17)。
要点
- 帕博利珠单抗联合地那昔利布在复发或难治性慢性淋巴细胞白血病中客观缓解率为29.4%(5/17)。
- 复发或难治性弥漫性大B细胞淋巴瘤客观缓解率为21.1%(8/38),复发或难治性多发性骨髓瘤为0%(0/17)。
- 联合方案总体耐受良好,未出现意外毒性;数据截止时全部72例患者均已停止治疗,38例(52.8%)因疾病进展。
核心结论
- 帕博利珠单抗联合地那昔利布显示出抗肿瘤活性,作者认为有必要以审慎和全面的方法探索抗PD-1与CDK9抑制剂联合方案。
研究设计与样本
- 多队列1期KEYNOTE-155研究,评估帕博利珠单抗联合地那昔利布在复发或难治性慢性淋巴细胞白血病、弥漫性大B细胞淋巴瘤和多发性骨髓瘤患者中的安全性和抗肿瘤活性。
- 入组患者年龄≥18岁,确诊慢性淋巴细胞白血病、弥漫性大B细胞淋巴瘤或多发性骨髓瘤;研究包括剂量评估阶段(确定剂量限制性毒性)和信号检测阶段。
- 共72例患者入组并接受至少1剂研究治疗:慢性淋巴细胞白血病17例,弥漫性大B细胞淋巴瘤38例,多发性骨髓瘤17例。
- 给药方案:帕博利珠单抗200 mg每3周一次,联合地那昔利布第1周期第1天7 mg/m2、第8天10 mg/m2,第2周期及以后第1天和第8天14 mg/m2。
- 主要终点为安全性,关键次要终点为客观缓解率。
主要发现
- 帕博利珠单抗联合地那昔利布总体耐受良好,未出现意外毒性。
- 客观缓解率:复发或难治性慢性淋巴细胞白血病29.4%(5/17),复发或难治性弥漫性大B细胞淋巴瘤21.1%(8/38),复发或难治性多发性骨髓瘤0%(0/17)。
- 数据截止时,全部72例患者均已停止治疗,其中38例(52.8%)因疾病进展停止治疗。
关键数值与推荐
- 客观缓解率:复发或难治性慢性淋巴细胞白血病29.4%(5/17),复发或难治性弥漫性大B细胞淋巴瘤21.1%(8/38),复发或难治性多发性骨髓瘤0%(0/17)。
- 因疾病进展停止治疗者38例(52.8%),全部72例患者均已停止治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preclinical data demonstrated that combining an anti-programmed cell death 1 (PD-1) inhibitor with a cyclin-dependent kinase 9 (CDK9) inhibitor provided enhanced antitumor activity with no significant toxicities, suggesting this combination may be a potential therapeutic option. The multicohort, phase 1 KEYNOTE-155 study evaluated the safety and antitumor activity of the PD-1 inhibitor pembrolizumab plus the CDK9 inhibitor dinaciclib in patients with relapsed or refractory (rr) chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Patients enrolled were ≥18 years of age with a confirmed diagnosis of CLL, DLBCL, or MM. The study included 2 phases: a dose-evaluation phase to determine dose-limiting toxicities and a signal-detection phase. Patients received pembrolizumab 200 mg every 3 weeks plus dinaciclib 7 mg/m2 on day 1 and 10 mg/m2 on day 8 of cycle 1 and 14 mg/m2 on days 1 and 8 of cycles 2 and later. Primary endpoint was safety, and a key secondary endpoint was objective response rate (ORR). Seventy-two patients were enrolled and received ≥1 dose of study treatment (CLL, n = 17; DLBCL, n = 38; MM, n = 17). Pembrolizumab plus dinaciclib was generally well tolerated and produced no unexpected toxicities. The ORRs were 29.4% (5/17, rrCLL), 21.1% (8/38, rrDLBCL), and 0% (0/17, rrMM), respectively. At data cutoff, all 72 patients had discontinued treatment, 38 (52.8%) because of progressive disease. These findings demonstrate activity with combination pembrolizumab plus dinaciclib and suggest that a careful and comprehensive approach to explore anti-PD-1 and CDK9 inhibitor combinations is warranted. This trial was registered at www.clinicaltrials.gov as NCT02684617.
引用
- Gregory GP, Kumar S, Wang D, et al. Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Adv. 2022. PMID: 34972202. doi:10.1182/bloodadvances.2021005872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。